VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Influenza A (H1N1) 2009 Monovalent Vaccine by CSL Limited Influenza A (H1N1) 2009 Monovalent Vaccine from MedImmune LLC
Vaccine Information Vaccine Information
  • Product Name: Influenza A (H1N1) 2009 Monovalent Vaccine
  • Manufacturer: CSL Limited
  • Vaccine Ontology ID: VO_0000348
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA
  • Host Species for Licensed Use: Human
  • Antigen: pandemic (H1N1) 2009 virus
  • Preparation: Influenza A (H1N1) 2009 Monovalent Vaccine is prepared from influenza virus propagated in the allantoic fluid of embryonated chicken eggs. Following harvest, the virus is purified in a sucrose density gradient using a continuous flow zonal centrifuge. The purified virus is inactivated with beta-propiolactone. The virus particles are disrupted using sodium taurodeoxycholate to produce a “split virion”. The disrupted virus is further purified and suspended in a phosphate buffered isotonic solution (FDA: CSL H1N1 vaccine).
  • Immunization Route: Intramuscular injection (i.m.)
  • Virulence: Inactivated.
  • Storage: store at 2−8°C (36−46°F)
  • Approved Age for Licensed Use: ages 18 years of age and older
  • Contraindication: Hypersensitivity to eggs or chicken protein, neomycin, or polymyxin, or life-threatening reaction to previous influenza vaccination.
  • Description: Influenza A (H1N1) 2009 Monovalent Vaccine, for intramuscular injection, is a sterile, clear, colorless to slightly opalescent suspension with some sediment that resuspends upon shaking to form a homogeneous suspension (FDA: CSL H1N1 vaccine).
  • Product Name: Influenza A (H1N1) 2009 Monovalent Vaccine
  • Manufacturer: MedImmune LLC
  • Vaccine Ontology ID: VO_0000349
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA
  • Host Species for Licensed Use: Human
  • Antigen: pandemic (H1N1) 2009 virus
  • Preparation: Specific pathogen-free (SPF) eggs are inoculated with the reassortant strain and incubated to allow vaccine virus replication. The allantoic fluid of these eggs is harvested, pooled and then clarified by filtration. The virus is concentrated by ultracentrifugation and diluted with stabilizing buffer to obtain the final sucrose and potassium phosphate concentrations. The viral harvests are then sterile filtered to produce monovalent bulks. Each lot is tested for ca, ts, and att phenotypes and is also tested extensively by in vitro and in vivo methods to detect adventitious agents. Monovalent bulks are diluted as required to attain the desired potency with stabilizing buffers. The bulk vaccine is then filled directly into individual sprayers for nasal administration (FDA: MedImmune H1N1 vaccine).
  • Immunization Route: Intramuscular injection (i.m.)
  • Virulence: Activated
  • Storage: INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE LIVE, INTRANASAL SHOULD BE STORED IN A REFRIGERATOR BETWEEN 2-8°C (35-46°F) UPON RECEIPT AND UNTIL USE. THE PRODUCT MUST BE USED BEFORE THE EXPIRATION DATE ON THE SPRAYER LABEL. DO NOT FREEZE (FDA: MedImmune H1N1 vaccine).
  • Approved Age for Licensed Use: ages 18 years of age and older
  • Contraindication: Hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or life threatening reactions to previous influenza vaccination. (4.1)
    Concomitant aspirin therapy in children and adolescents. (4.2) Safety and effectiveness of Influenza A (H1N1) 2009 Monovalent
  • Description: Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is a live monovalent vaccine for administration by intranasal spray. It is (a) cold-adapted (i.e., it replicates efficiently at 25 C, a temperature that is restrictive for replication of many wild- type influenza viruses); (b) temperature-sensitive (ts) (i.e., it is restricted in replication at 39 C, a temperature at which many wild-type influenza viruses grow efficiently); and (c) attenuated (it does not produce classic influenza-like illness in the ferret model of human influenza infection). The attenuated vaccine virus replicates in the nasopharynx to induce protective immunity (FDA: MedImmune H1N1 vaccine).
Host Response Host Response

Bear Response

  • Vaccination Protocol: A single 0.5 mL intramuscular injection (FDA: CSL H1N1 vaccine).
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: The most common (≥ 10%) local (injection-site) adverse reactions are tenderness, pain, redness, and swelling. The most common (≥ 10%) systemic adverse reactions are headache, malaise, and muscle aches (FDA: CSL H1N1 vaccine).

Bear Response

  • Immune Response Assay Type: HI antibody assay
  • Side Effects: Most common adverse reactions (≥ 10% in FluMist and at least 5% greater
    than in control) are runny nose or nasal congestion in all ages, fever >100°F in
    children 2-6 years of age, and sore throat in adults. (6.1)
References References
FDA: CSL H1N1 vaccine: FDA: the H1N1 influenza vaccine from CSL [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181975.htm]
FDA: MedImmune H1N1 vaccine: Influenza A (H1N1) 2009 Monovalent Vaccine (MedImmune LLC) [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181970.htm]